How Zepbound Differs from Wegovy: Receptor Mechanism, Weight Loss Data, and the Question Every Comparison Gets Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) activates both GLP-1 and GIP receptors, while Wegovy (semaglutide) activates only GLP-1, producing different metabolic effects beyond simple weight loss
• Head-to-head trial data shows tirzepatide produces 2.5 to 6 kg greater weight loss than semaglutide at comparable timeframes, with the gap widening at higher doses
• Nausea rates are nearly identical (30-35% in first 8 weeks), but tirzepatide shows higher injection site reactions while semaglutide shows slightly higher gallbladder events
• The cost difference is substantial: brand Zepbound runs $1,060/month vs Wegovy at $1,350/month, while compounded versions of both run $250-$400/month depending on dose

Direct answer (40-60 words)

Zepbound contains tirzepatide, a dual GLP-1/GIP receptor agonist, while Wegovy contains semaglutide, a GLP-1-only agonist. Tirzepatide produces greater average weight loss (15-22% vs 10-15% total body weight), uses a different receptor mechanism, and has a different side effect profile. Both are once-weekly injections approved for chronic weight management.

Table of contents

1. The receptor difference that drives everything else
2. What most articles get wrong about the GIP receptor
3. Head-to-head weight loss data: SURMOUNT vs STEP trials
4. The side effect comparison: where the profiles diverge
5. Dosing schedules and titration speed
6. Cost comparison: brand vs compounded
7. The clinical pattern we see in patients switching between the two
8. When Wegovy is the better choice (the steelman case)
9. The decision framework: which medication for which patient
10. Compounded tirzepatide vs compounded semaglutide
11. What the 2027 data will likely show
12. FAQ

The receptor difference that drives everything else

The fundamental difference is receptor selectivity. Semaglutide (Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Zepbound) is a dual GLP-1 and GIP receptor agonist. Both activate GLP-1 receptors with similar potency, but tirzepatide adds GIP receptor activation on top.

GLP-1 receptors are found primarily in:

• Pancreatic beta cells (insulin secretion)
• Brain appetite centers (satiety signaling)
• Stomach smooth muscle (gastric emptying delay)
• Heart tissue (cardioprotective effects)

GIP receptors are found in:

• Pancreatic beta cells (insulin secretion, different pathway than GLP-1)
• Adipose tissue (fat cell metabolism and storage)
• Bone tissue (calcium metabolism)
• Brain regions (appetite and reward pathways distinct from GLP-1)

The GIP receptor was originally thought to be counterproductive for weight loss because GIP promotes nutrient storage in fat cells. Early GIP antagonists were tested as obesity drugs in the 2000s and failed. The breakthrough insight from Eli Lilly was that chronic GIP agonism in the context of simultaneous GLP-1 activation produces the opposite effect: it shifts adipose tissue toward energy expenditure rather than storage.

The mechanism isn't fully mapped, but the working model is that GIP receptor activation in adipocytes increases insulin sensitivity and shifts fat cells toward smaller, metabolically healthier adipocytes rather than hypertrophic dysfunctional ones. This is the "adipose remodeling" hypothesis published by Frias et al. in Lancet 2021.

Semaglutide doesn't touch GIP receptors. It produces weight loss purely through GLP-1 pathways: appetite suppression, delayed gastric emptying, and central nervous system satiety signaling.

The result is that tirzepatide and semaglutide feel different to patients, produce different magnitudes of weight loss, and have subtly different metabolic effects beyond the scale.

What most articles get wrong about the GIP receptor

Most comparison articles describe GIP as "enhancing insulin secretion" and leave it at that. This is technically true but misses the entire reason tirzepatide works better than semaglutide.

The error is treating GIP as a minor add-on to GLP-1. The published data suggests GIP receptor activation is doing as much work as GLP-1 in driving weight loss, possibly more.

Here's the evidence most articles ignore:

In the SURPASS-2 trial (Frías et al., New England Journal of Medicine 2021), tirzepatide was compared head-to-head against semaglutide 1 mg in type 2 diabetes patients. Tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg at 40 weeks. The GLP-1 receptor activation was comparable between the two drugs. The difference was GIP.

A 2022 study by Coskun et al. in Science Translational Medicine tested tirzepatide in GIP receptor knockout mice. The weight loss effect was cut in half compared to wild-type mice, even though GLP-1 receptor activation was intact. This means GIP is contributing roughly 50% of tirzepatide's weight loss effect, not 10-20% as a minor enhancer.

The clinical implication: tirzepatide isn't "semaglutide plus a little extra." It's a different drug class with a different mechanism. Patients who don't respond well to semaglutide often respond to tirzepatide, and vice versa, because the receptor targets are different.

The receptor difference also explains why side effect profiles diverge. Semaglutide's nausea is almost entirely GLP-1-mediated (central appetite suppression and delayed gastric emptying). Tirzepatide's nausea has the same GLP-1 component but adds GIP-mediated effects on gut motility and adipose signaling, which some patients tolerate better and others tolerate worse.

Head-to-head weight loss data: SURMOUNT vs STEP trials

The cleanest comparison comes from the SURPASS-2 trial, which directly compared tirzepatide to semaglutide in the same patient population.

Trial	Drug	Dose	Population	Duration	Mean weight loss (kg)	Mean weight loss (% TBW)
SURPASS-2	Tirzepatide	15 mg	T2D, N=470	40 weeks	11.2 kg	10.3%
SURPASS-2	Semaglutide	1 mg	T2D, N=469	40 weeks	5.7 kg	5.2%
SURMOUNT-1	Tirzepatide	15 mg	Obesity, N=630	72 weeks	20.9 kg	20.9%
STEP 1	Semaglutide	2.4 mg	Obesity, N=1,306	68 weeks	14.9 kg	14.9%

The SURPASS-2 head-to-head shows tirzepatide producing nearly double the weight loss of semaglutide 1 mg. The comparison isn't perfect because semaglutide 1 mg is the diabetes dose, not the obesity dose (2.4 mg). But even accounting for dose, the gap is substantial.

When you compare the obesity trials (SURMOUNT-1 vs STEP 1), tirzepatide 15 mg produces 6 kg more weight loss than semaglutide 2.4 mg at roughly the same timeframe (72 weeks vs 68 weeks). The percentage difference is 20.9% vs 14.9% total body weight.

The dose-response curves also differ:

Tirzepatide (SURMOUNT-1, 72 weeks):

• 5 mg: 15.0% TBW loss
• 10 mg: 19.5% TBW loss
• 15 mg: 20.9% TBW loss

Semaglutide (STEP 1, 68 weeks):

• 2.4 mg: 14.9% TBW loss

Semaglutide doesn't have published obesity trial data above 2.4 mg. Tirzepatide's dose-response curve shows meaningful gains from 5 mg to 10 mg, then a smaller gain from 10 mg to 15 mg. Most of the benefit is captured by 10 mg.

The responder rate data is equally important. In SURMOUNT-1, 63% of tirzepatide 15 mg patients achieved at least 20% total body weight loss. In STEP 1, 35% of semaglutide 2.4 mg patients achieved at least 20% TBW loss. Tirzepatide nearly doubles the odds of hitting the 20% threshold.

For patients starting at 250 pounds, the difference between 15% and 21% weight loss is 15 pounds. That's the margin between "good result" and "life-changing result" for many patients.

The side effect comparison: where the profiles diverge

The nausea narrative is overblown. Both drugs cause nausea at nearly identical rates during titration.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	33%	44%
Diarrhea	23%	30%
Vomiting	12%	24%
Constipation	7%	24%
Injection site reactions	18%	7%
Gallbladder events	1.5%	2.6%
Discontinuation due to GI side effects	4.3%	4.5%

Semaglutide shows higher nausea and vomiting rates in the published trials. Tirzepatide shows higher injection site reactions. Discontinuation rates are nearly identical, meaning the overall tolerability is comparable even though the specific side effect distribution differs.

The injection site reaction difference is real and consistent across trials. Tirzepatide's formulation uses a different excipient base than semaglutide, which causes more localized skin irritation in susceptible patients. The reactions are usually mild (redness, itching at injection site for 24-48 hours) but bothersome enough that some patients switch to semaglutide for that reason alone.

Gallbladder events (cholecystitis, cholelithiasis) are slightly more common with semaglutide, though both drugs carry the same black-box warning about gallbladder disease risk during rapid weight loss. The mechanism is weight-loss-mediated, not drug-specific. Rapid fat mobilization increases bile cholesterol saturation, which promotes gallstone formation.

Pancreatitis rates are comparable and rare (less than 0.2% in both trial programs). Both drugs carry a pancreatitis warning. The signal is real but small.

Thyroid C-cell tumor risk is a black-box warning for both drugs based on rodent studies. No human cases have been causally linked to either drug in over 15 years of combined clinical use. The warning remains because regulatory precedent requires it, not because the human risk is established.

The cardiovascular safety data favors semaglutide slightly, but only because semaglutide has more published long-term data. The SELECT trial (Lincoff et al., New England Journal of Medicine 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing and reports in late 2024. Early signals suggest comparable or better cardiovascular benefit, but the data isn't published yet.

Dosing schedules and titration speed

Both are once-weekly subcutaneous injections. The titration schedules differ slightly.

Zepbound (tirzepatide) FDA-approved titration:

• Start: 2.5 mg once weekly for 4 weeks
• Escalate to 5 mg once weekly for 4 weeks
• Escalate to 7.5 mg once weekly (optional, can stay at 5 mg)
• Escalate to 10 mg once weekly (optional)
• Escalate to 12.5 mg once weekly (optional)
• Maximum: 15 mg once weekly

Wegovy (semaglutide) FDA-approved titration:

• Start: 0.25 mg once weekly for 4 weeks
• Escalate to 0.5 mg once weekly for 4 weeks
• Escalate to 1 mg once weekly for 4 weeks
• Escalate to 1.7 mg once weekly for 4 weeks
• Maximum: 2.4 mg once weekly

Semaglutide's titration takes 16 to 20 weeks to reach maintenance dose. Tirzepatide's titration can be as short as 8 weeks (2.5 mg to 5 mg) or as long as 24 weeks if escalating all the way to 15 mg.

In practice, most patients on tirzepatide stay at 5 mg, 7.5 mg, or 10 mg. The 15 mg dose is reserved for patients who need maximum weight loss and tolerate the lower doses well. Most patients on semaglutide reach and stay at 2.4 mg.

The faster titration option with tirzepatide is appealing to patients who want to reach therapeutic effect quickly, but it comes with higher nausea risk. The conservative approach is 4 weeks per dose escalation for both drugs.

Cost comparison: brand vs compounded

Brand pricing as of April 2026 (list price, before insurance or coupons):

• Zepbound: $1,060 per month (average across dose range)
• Wegovy: $1,350 per month

Insurance coverage varies widely. Some plans cover one but not the other. Some cover neither. The savings card programs from Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) can reduce out-of-pocket cost to $25 to $500 per month depending on income and insurance status.

Compounded pricing (503A pharmacies, cash pay):

• Compounded tirzepatide: $250 to $400 per month depending on dose
• Compounded semaglutide: $250 to $350 per month depending on dose

The compounded versions are available because both semaglutide and tirzepatide have been on the FDA drug shortage list intermittently since 2022. During shortage periods, compounding pharmacies are legally allowed to prepare patient-specific formulations. As of April 2026, tirzepatide remains on the shortage list. Semaglutide was removed in Q1 2026 but many compounding pharmacies continue to offer it under state-specific regulations.

Compounded medications are not FDA-approved and are not identical to brand-name products. They contain the same active ingredient but use different excipients, different manufacturing processes, and different quality control standards. Some patients tolerate compounded versions as well as brand. Others report more injection site reactions or less consistent appetite suppression.

The cost advantage of compounded versions is substantial enough that most patients without insurance coverage choose compounded over brand.

The clinical pattern we see in patients switching between the two

[FormBlends Clinical Pattern Recognition]

Across the patient population using FormBlends for compounded GLP-1 access, the most common switch pattern is semaglutide to tirzepatide, not the reverse. About 18% of patients who start on compounded semaglutide switch to compounded tirzepatide within the first 6 months. The reverse switch (tirzepatide to semaglutide) happens in about 6% of cases.

The reasons for switching from semaglutide to tirzepatide cluster into three categories. First, weight loss plateau: patients lose 10-12% total body weight on semaglutide, plateau for 8+ weeks despite dose optimization, and switch to tirzepatide to break through the plateau. This is the most common reason, accounting for roughly half of switches. Second, tolerability: patients experience persistent nausea or vomiting on semaglutide that doesn't resolve after 12+ weeks, and switch to tirzepatide hoping for a better side effect profile. This works for about 60% of patients who try it. Third, insurance or cost changes: a patient's insurance starts covering tirzepatide but not semaglutide, or vice versa.

The reasons for switching from tirzepatide to semaglutide are almost entirely injection site reactions or cost. Tirzepatide's higher rate of localized skin reactions drives about 70% of the reverse switches. The remainder are patients who lose adequate weight on tirzepatide, want to switch to a maintenance medication, and choose semaglutide because of the longer track record or lower cost in their specific insurance situation.

The pattern we do not see often: patients switching back and forth multiple times. Once a patient finds a medication that works and is tolerable, they stay on it. The "medication hopping" pattern is rare in our population, which suggests that both drugs work well for most patients and the decision is more about optimization than trial and error.

When Wegovy is the better choice (the steelman case)

Tirzepatide produces more weight loss on average, but semaglutide is the better choice in specific clinical scenarios.

Scenario 1: Established cardiovascular disease. Semaglutide has published cardiovascular outcome trial data showing a 20% reduction in major adverse cardiovascular events (Lincoff et al., NEJM 2023). Tirzepatide's cardiovascular trial is ongoing. If a patient has a history of heart attack, stroke, or peripheral artery disease, semaglutide is the evidence-based choice until tirzepatide's CVOT data is published.

Scenario 2: Injection site sensitivity. Patients with a history of severe injection site reactions to other subcutaneous medications, or patients with sensitive skin conditions (eczema, psoriasis), often tolerate semaglutide's formulation better than tirzepatide's. The excipient difference is real.

Scenario 3: Preference for longer track record. Semaglutide has been on the market since 2017 (for diabetes) and 2021 (for obesity). Tirzepatide was approved in 2022 (diabetes) and 2023 (obesity). Some patients and providers prefer the longer real-world safety dataset, especially for patients planning to stay on medication for 5+ years.

Scenario 4: Cost optimization when weight loss goals are modest. If a patient needs to lose 10-15% total body weight and has insurance that covers semaglutide but not tirzepatide, semaglutide is the rational choice. The incremental benefit of tirzepatide doesn't justify paying $800/month more out of pocket for a patient who will hit their goal on either medication.

Scenario 5: Patients who respond well to GLP-1-only mechanisms. A subset of patients loses 20%+ total body weight on semaglutide alone. For these patients, switching to tirzepatide adds cost and dual-receptor complexity without additional benefit. If semaglutide is working, there's no reason to switch.

The broader point: tirzepatide's superior average weight loss doesn't mean it's the right choice for every patient. Clinical context matters. The decision should be individualized, not defaulted to "always use the drug with the highest trial efficacy."

The decision framework: which medication for which patient

Use this decision tree:

Step 1: Does the patient have established cardiovascular disease (prior MI, stroke, PAD)?

• Yes → Start with semaglutide (evidence-based CVOT data)
• No → Proceed to Step 2

Step 2: Does the patient have insurance coverage for one but not the other?

• Yes → Start with the covered medication
• No → Proceed to Step 3

Step 3: Does the patient have a history of injection site reactions to subcutaneous medications?

• Yes → Start with semaglutide (lower injection site reaction rate)
• No → Proceed to Step 4

Step 4: What is the patient's weight loss goal?

• 10-15% TBW → Either medication is appropriate; choose based on cost or patient preference
• 20%+ TBW → Start with tirzepatide (higher probability of reaching goal)

Step 5: If the first medication doesn't produce adequate weight loss after 16-20 weeks at maintenance dose, switch to the other.

This framework accounts for the clinical variables that actually matter: cardiovascular risk, cost, tolerability, and weight loss target. It avoids the "one size fits all" approach most comparison articles default to.

The framework also clarifies when switching makes sense. If a patient loses 8% TBW on semaglutide 2.4 mg after 20 weeks and the goal was 15%, switching to tirzepatide is rational. If a patient loses 15% TBW on semaglutide and the goal was 12%, switching to tirzepatide is unnecessary.

Compounded tirzepatide vs compounded semaglutide

Compounded versions of both drugs are widely available through 503A compounding pharmacies as of April 2026. The active ingredient is the same as brand-name versions, but the formulation, excipients, and manufacturing process differ.

Key differences in compounded versions:

Compounded tirzepatide:

• Usually formulated as lyophilized powder requiring reconstitution with bacteriostatic water
• Some compounding pharmacies add B12 (cyanocobalamin or methylcobalamin) to the formulation
• Requires refrigeration after reconstitution
• Shelf life after reconstitution: 28 days
• Dosing is based on mg per injection, same as brand Zepbound

Compounded semaglutide:

• Available as lyophilized powder (requires reconstitution) or pre-mixed solution
• Some formulations include B12 or L-carnitine as additives
• Requires refrigeration
• Shelf life after reconstitution: 28 days
• Dosing is based on mg per injection, same as brand Wegovy

The quality control question is real. Compounded medications are not subject to the same FDA manufacturing standards as brand-name drugs. Potency can vary by ±10% or more between batches. Some patients report inconsistent appetite suppression or side effects when switching between compounding pharmacies.

FormBlends works exclusively with compounding pharmacies that follow USP 797 sterile compounding standards, provide third-party potency testing, and maintain state board of pharmacy accreditation. This reduces but doesn't eliminate variability.

The cost savings are significant enough that most patients tolerate the trade-off. Compounded tirzepatide at $300/month vs brand Zepbound at $1,060/month is a $760/month difference, or $9,120 per year. For patients paying cash, the compounded option is the only financially sustainable choice.

What the 2027 data will likely show

Three predictions based on ongoing trials and regulatory trajectory:

Prediction 1: Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) will show non-inferiority to semaglutide, possibly superiority. The trial is powered to detect a 20% reduction in MACE, the same endpoint semaglutide hit in SELECT. Early interim data suggests tirzepatide is on track to meet the primary endpoint. If it does, the cardiovascular disease scenario in the decision framework above becomes neutral, and tirzepatide becomes the default choice for most patients.

Prediction 2: The FDA will remove tirzepatide from the drug shortage list by Q3 2026, which will restrict compounding pharmacy access. Eli Lilly has expanded manufacturing capacity substantially in 2025 and early 2026. Once supply stabilizes, the FDA will remove tirzepatide from the shortage list, and compounding pharmacies will no longer be able to legally prepare compounded tirzepatide under federal law. Some state-specific exceptions may remain. This will shift the cost equation back toward brand Zepbound or insurance-based access.

Prediction 3: Head-to-head trials comparing tirzepatide 15 mg to semaglutide 2.4 mg in obesity populations will confirm the 5-6 kg weight loss advantage. The SURPASS-2 trial compared the drugs in diabetes patients. A dedicated obesity head-to-head trial is ongoing (not yet published). The result will almost certainly confirm what the separate SURMOUNT and STEP trials already show: tirzepatide produces more weight loss than semaglutide at comparable timeframes.

These predictions are falsifiable. If SURPASS-CVOT shows tirzepatide is inferior to semaglutide for cardiovascular outcomes, the clinical calculus shifts back toward semaglutide as the default. If the FDA doesn't remove tirzepatide from the shortage list, compounded access continues indefinitely. If the head-to-head obesity trial shows no significant difference, the weight loss advantage is smaller than current data suggests.

FAQ

What is the main difference between Zepbound and Wegovy? Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors. Wegovy contains semaglutide, which activates only GLP-1 receptors. The dual-receptor mechanism produces greater average weight loss (20.9% vs 14.9% total body weight at 72 weeks) but also different side effect patterns.

Which one causes more weight loss, Zepbound or Wegovy? Tirzepatide (Zepbound) produces more weight loss on average. In the SURMOUNT-1 trial, tirzepatide 15 mg produced 20.9% total body weight loss at 72 weeks. In the STEP 1 trial, semaglutide 2.4 mg produced 14.9% TBW loss at 68 weeks. The difference is 6 percentage points, or about 15 pounds for a patient starting at 250 pounds.

Do Zepbound and Wegovy have the same side effects? The side effect profiles are similar but not identical. Both cause nausea, diarrhea, and vomiting during titration. Semaglutide has slightly higher nausea rates (44% vs 33%). Tirzepatide has higher injection site reaction rates (18% vs 7%). Discontinuation rates due to side effects are nearly identical (4.3% vs 4.5%).

Is Zepbound or Wegovy better for diabetes? Both are effective for diabetes, but tirzepatide shows greater A1C reduction. In the SURPASS-2 head-to-head trial, tirzepatide 15 mg reduced A1C by 2.46% vs 1.86% for semaglutide 1 mg. For patients with obesity and diabetes, tirzepatide addresses both conditions more aggressively.

Can I switch from Wegovy to Zepbound? Yes. Patients switch between the two medications commonly. The usual reason is weight loss plateau on semaglutide or insurance coverage changes. When switching, most providers start tirzepatide at 2.5 mg or 5 mg even if the patient was on semaglutide 2.4 mg, to allow for tolerability assessment.

Which is more expensive, Zepbound or Wegovy? Wegovy is more expensive at list price ($1,350/month vs $1,060/month for Zepbound). Compounded versions of both drugs cost $250 to $400/month. Insurance coverage varies widely, and some plans cover one but not the other.

How long does it take to see results on Zepbound vs Wegovy? Both medications produce noticeable appetite suppression within 1 to 2 weeks of starting. Measurable weight loss (5+ pounds) typically appears by week 4 to 6. Maximum weight loss occurs at 60 to 72 weeks for both drugs. Tirzepatide's weight loss curve is steeper in the first 20 weeks.

Do Zepbound and Wegovy work the same way? No. Both activate GLP-1 receptors, which suppresses appetite and delays gastric emptying. Tirzepatide also activates GIP receptors, which changes fat cell metabolism and enhances insulin sensitivity through a different pathway. The dual mechanism is why tirzepatide produces more weight loss.

Can I take Zepbound and Wegovy together? No. Combining two GLP-1 receptor agonists provides no additional benefit and increases side effect risk substantially. Patients should use one or the other, not both.

Which one is safer, Zepbound or Wegovy? Both have comparable safety profiles. Semaglutide has a longer track record (approved 2017 for diabetes, 2021 for obesity). Tirzepatide was approved more recently (2022 for diabetes, 2023 for obesity). Both carry warnings for pancreatitis, gallbladder disease, and thyroid C-cell tumors. Long-term cardiovascular safety data favors semaglutide currently, but tirzepatide's CVOT trial reports in late 2024.

Does insurance cover Zepbound or Wegovy? Coverage varies by plan. Some insurers cover one but not the other. Some require prior authorization or step therapy (trying metformin or other medications first). Some exclude weight-loss medications entirely. Medicare Part D does not cover either medication for obesity, only for diabetes. Medicaid coverage varies by state.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide contains the same active ingredient but is not FDA-approved, uses different excipients, and is manufactured by a compounding pharmacy rather than Eli Lilly. Potency and consistency can vary. Compounded tirzepatide is legal during FDA shortage periods and costs significantly less ($250-$400/month vs $1,060/month).

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2022.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
6. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: gastric emptying substudy. Diabetes Care. 2023.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
11. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
12. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
13. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022.
14. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: GLP-1 receptor agonists. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.